Advantage Alpha Capital Partners LP Invests $417,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Advantage Alpha Capital Partners LP acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,289 shares of the company’s stock, valued at approximately $417,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co boosted its position in shares of Krystal Biotech by 80.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock worth $557,000 after purchasing an additional 1,397 shares during the period. Lazard Asset Management LLC boosted its holdings in Krystal Biotech by 27.5% in the 1st quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after buying an additional 282 shares during the period. Caxton Associates LP purchased a new stake in Krystal Biotech in the 1st quarter worth $232,000. Virtu Financial LLC bought a new stake in Krystal Biotech during the first quarter valued at about $640,000. Finally, GAMMA Investing LLC raised its holdings in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 1.0 %

Krystal Biotech stock opened at $196.52 on Wednesday. Krystal Biotech, Inc. has a 52-week low of $99.00 and a 52-week high of $219.34. The firm’s fifty day moving average is $179.69 and its 200 day moving average is $183.09. The company has a market cap of $5.65 billion, a price-to-earnings ratio of 111.03 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.67) EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on KRYS shares. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $202.29.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).